ONCOTELIC CLOSES COVID-19 CLINICAL TRIAL EARLY.
June 15, 2021 09:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, California, June 15, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic" or the “Company”), a leading developer of TGF-β therapeutics for oncology,...
MATEON ANNOUNCES FIRST PATIENT ENROLLED IN ARTI-19: A MULTICENTER INTERVENTIONAL STUDY OF ARTISHIELD™ AGAINST COVID-19
October 07, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
TOP-LINE DATA ANTICIPATED IN FOURTH QUARTER 2020 AGOURA HILLS, California, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β...
MATEON IS SELECTED BY IBM WATSON HEALTH FOR THE USE OF IBM CLINICAL DEVELOPMENT SOLUTION AT NO COST FOR PHASE II CLINICAL TRIAL OF OT-101 FOR COVID-19
June 24, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates AGOURA HILLS,...
Oncotelic Reports Clinical Validation of Drug Induce Xenogenization (DIX) For Treatment of Glioblastoma and Pancreatic Cancer (PC)
March 04, 2019 09:00 ET
|
Oncotelic Inc
Phase 2 Clinical Data Presented at ASCO-SITC Clinical Immuno-Oncology SymposiumXenogenization through chemotherapy-induced genetic mutations (alkylating agents such as temozolomide) or drug-induced...